Difference with ACR is that it was using a previously used drug that has been around for a long time and very well studied , but utilising a difference administration method so the chances of it succeeding were much higher than trof
The risk with partnering trof is phase 3 fail - we get stuff all
They would definitely reapply for BT - I look at the first application as a blind test to feel out FDA. They would have learnt a lot from that . Mistake was - they should have kept in house!!
At end of the day we can all speculate time will tell but none the less this is very exciting for all . Regardless we have 2 X positive p2 - that is worth a lot more then what we are siting at regardless of external market conditions
Difference with ACR is that it was using a previously used drug...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 6644 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |